Tunisian Pharmaceutical Industries Company (Siphat) Resumes Production of Injectable Solutions
The Tunisian Pharmaceutical Industries Company (Siphat) has announced the resumption of production of injectable solutions, following a meeting held on September 18, 2024, under the presidency of the Minister of Health. This measure aims to ensure the supply of essential medicines to the national market and strengthen pharmaceutical security in Tunisia.
During this meeting, key decisions were made to improve the company's performance. Siphat will increase its production, particularly by doubling the volume of injectable solutions to meet national needs.
According to an official statement, the company will also resume the manufacture of medicines and medical equipment, thereby optimizing its role in the health sector. These initiatives will contribute to reducing dependence on imports and strengthening the country's autonomy in pharmaceutical products.
To ensure the quality of products, Siphat will implement strict controls at every stage of the process, from production to distribution. The digitalization of production and distribution chains will also improve the efficiency and traceability of medicines and medical equipment. The Minister emphasized the need for effective human resource management to meet production needs, while filling essential vacant positions.
The Minister of Health highlighted the strategic role of Siphat in the national pharmaceutical security system. He called for continuous evaluation of the company's performance and improvement of its capabilities through the use of new technologies. The fight against corruption and promotion of transparency within the company were also emphasized as essential elements to maintain trust in its crucial role.
By strengthening its production and improving its management, Siphat directly contributes to pharmaceutical security in Tunisia, ensuring better access to medicines for the population.
